ClearPoint Neuro, Inc. has amended its existing equity offering agreement to increase the total amount of proceeds the company can raise through an at-the-market (ATM) sales program. The company entered into the original agreement with Stifel, Nicolaus & Company, Incorporated in November 2024, allowing for the sale of common stock with aggregate sales proceeds of up to $50 million.
On November 18, 2026, ClearPoint Neuro and Stifel executed an amendment to this agreement. The new agreement raises the total potential aggregate sales proceeds from $50 million to $150 million. This cap includes the proceeds already raised under the original agreement.
As of the date of the filing, ClearPoint Neuro has sold approximately $22.5 million worth of shares under the original agreement. The company utilized its existing registration statement on Form S-3 (File No. 333-275476), declared effective by the SEC on November 20, 2023, along with a related prospectus supplement filed on November 7, 2024.
The amendment indicates that the amount of shares currently available for offer and sale under the existing prospectus supplement is approximately $27.5 million. If the company wishes to offer additional shares beyond this amount, it will need to file a new prospectus supplement.
Under the terms of the agreement, Stifel will act as sales agent to sell shares from time to time based on the company's instructions. The agent is entitled to a commission of up to 3.0% of the gross sales price of the shares sold and will be reimbursed for specified expenses. The agreement allows the company to suspend offers at any time and may be terminated by either party with written notice.